Voyager Therapeutics Inc

For the period ended Mar 31, 2025. Filed May 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

VYGR$1.83-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(amounts in thousands, except share and per share data)


· · Three Months Ended ·
· · March 31,
· · 2025 · · 2024
Collaboration revenue (including from related parties, see note 12)	$6,473	$19,516
Operating expenses:
Research and development	31,526	27,092
General and administrative	9,640	8,607
Total operating expenses	41,166	35,699
Operating loss	(34,693)	(16,183)
Other income, net:
Interest income	3,291	4,867
Other income	418	—
Total other income, net	3,709	4,867
Loss before income taxes	(30,984)	(11,316)
Income tax provision	37	14
Net loss	$(31,021)	$(11,330)
Other comprehensive gain (loss):
Net unrealized gain (loss) on available-for-sale securities	208	(458)
Total other comprehensive gain (loss)	208	(458)
Comprehensive loss	$(30,813)	$(11,788)
Net loss per share, basic	$(0.53)	$(0.20)
Net loss per share, diluted	$(0.53)	$(0.20)
Weighted-average common shares outstanding, basic	58,349,769	57,117,046
Weighted-average common shares outstanding, diluted	58,349,769	57,117,046

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.